Palisade Bio, Inc. Share Price
PALIPalisade Bio, Inc. Stock Performance
Open $1.85 | Prev. Close $1.88 | Circuit Range N/A |
Day Range $1.84 - $2.03 | Year Range $0.53 - $2.85 | Volume 1,40,699 |
Average Traded $1.98 |
Palisade Bio, Inc. Share Price Chart
About Palisade Bio, Inc.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn's disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California.
Palisade Bio, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
17-Jul-26 | $1.85 | $1.96 | +4.81% |
16-Jul-26 | $2.03 | $1.87 | -7.65% |
15-Jul-26 | $1.92 | $2.02 | +4.92% |
14-Jul-26 | $1.91 | $1.93 | +1.85% |
13-Jul-26 | $1.99 | $1.90 | -3.81% |
10-Jul-26 | $1.98 | $1.97 | +0.51% |
09-Jul-26 | $2.11 | $1.96 | -4.39% |